These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1144 related articles for article (PubMed ID: 34365406)

  • 21. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    Manabe T; Bivona TG
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The KRAS-G12C inhibitor: activity and resistance.
    Liu J; Kang R; Tang D
    Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
    Bauml JM; Li BT; Velcheti V; Govindan R; Curioni-Fontecedro A; Dooms C; Takahashi T; Duda AW; Odegaard JI; Cruz-Guilloty F; Jin L; Zhang Y; Anderson A; Skoulidis F
    Lung Cancer; 2022 Apr; 166():270-278. PubMed ID: 34838325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
    Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM
    J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS
    Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT
    N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
    Mohanty A; Nam A; Srivastava S; Jones J; Lomenick B; Singhal SS; Guo L; Cho H; Li A; Behal A; Mirzapoiazova T; Massarelli E; Koczywas M; Arvanitis LD; Walser T; Villaflor V; Hamilton S; Mambetsariev I; Sattler M; Nasser MW; Jain M; Batra SK; Soldi R; Sharma S; Fakih M; Mohanty SK; Mainan A; Wu X; Chen Y; He Y; Chou TF; Roy S; Orban J; Kulkarni P; Salgia R
    Sci Adv; 2023 Oct; 9(41):eade3816. PubMed ID: 37831779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sotorasib for previously treated colorectal cancers with KRAS
    Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
    Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
    de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
    Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR Blockade Reverts Resistance to KRAS
    Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
    Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.
    Zhang Y; Liu L; Pei J; Ren Z; Deng Y; Yu K
    Oncogene; 2024 Feb; 43(9):668-681. PubMed ID: 38191673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
    Lindsay CR; Garassino MC; Nadal E; Öhrling K; Scheffler M; Mazières J
    Lung Cancer; 2021 Oct; 160():152-165. PubMed ID: 34417059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
    Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
    Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The promise and peril of KRAS G12C inhibitors.
    Moore AR; Malek S
    Cancer Cell; 2021 Aug; 39(8):1059-1061. PubMed ID: 34375610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sotorasib: a KRAS
    Ganguly A; Yoo E
    Trends Pharmacol Sci; 2022 Jun; 43(6):536-537. PubMed ID: 35461718
    [No Abstract]   [Full Text] [Related]  

  • 38. Sotorasib: First Approval.
    Blair HA
    Drugs; 2021 Sep; 81(13):1573-1579. PubMed ID: 34357500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced
    Thummalapalli R; Bernstein E; Herzberg B; Li BT; Iqbal A; Preeshagul I; Santini FC; Eng J; Ladanyi M; Yang SR; Shen R; Lito P; Riely GJ; Sabari JK; Arbour KC
    JCO Precis Oncol; 2023 Jun; 7():e2300030. PubMed ID: 37384866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.